As the functional units, the most clinically important molecules in our bodies are proteins and proteoforms. Variations in the concentration of specific blood proteins can reveal various health or disease conditions for disease diagnosis and therapy monitoring. When proteins are sufficiently studied and characterized, they can also be effective and safer drugs to treat patients.

​

The company founders are world-class innovators in science and business with decades of experience and track of success in the Life Sciences sector. QuantaPro’s biomarker testing and therapeutic products and services aimed at cancer, obesity, liver toxicity, diabetes, cardiovascular and healthy/longer aging are all based on biomolecules that are innovative, disruptive and transformative. All QuantaPro discoveries and tests are done on a single universal molecular detector system, the LC-MS.

There is a huge opportunity to find and patent protein segments for new tests and therapeutics. To date, less than 3,000 proteins tested by the mass spectrometer (MS) are characterized enough to merit health-related applications. More than 17,000 plasma proteins and up to 100,000 proteoforms await discovery, validation and development as clinical tests and drugs.

 

Proteins are fragile compounds with complex molecular structures that are critical for their functionality. There hasn’t been an instrument, method or technology that can discover, validate and test target proteins directly and provide access to global population until now. QuantaPro has the solution in integrated dual technologies, Thor’s Hammer (TH) and Actionable Dry Blood Spots (ADBS).

 

Within-reach-approach to healthcare is of paramount importance. Yet, the largest segments of the world’s population do not have access to the most basic types of testing.

One impediment is the invasive phlebotomy blood-draw with syringe and needle, the other is the cost. ADBS is the solution. When the blood on ADBS dries, most biological processes, such as enzymatic reactions stop. Drying also inactivates microbes and viruses. Compared to liquid whole blood, dry blood on the DBS is stable much longer, can be stored at room temperature, much less expensive and safe to globally transport by ordinary mail. 

 

Although a drop of blood sample collected on dried blood spots (DBS) is simple and easy to obtain, their use in healthcare has been limited. DBS-sampled-test that can produce clinically actionable data quality has not been available until now. The results of QuantaPro’s Actionable DBS exceed FDA’s analytical test quality requirements (accuracy and precision) and are equivalent to phlebotomy blood draw results. Offered as affordable self-sample-collection test kits, ADBS will provide global access to medical testing and improved healthcare.

 

QuantaPro aims to overcome barriers and address pent-up demands in the healthcare field with

• a single universal detector and a fundamentally different, direct quantification method applicable to all proteins and biomolecules

• new protein-biomarker discoveries with a transformative signal amplification technology

• protein-biomarker testing for health and disease diagnosis with actionable accuracy and precision

• protein-drug development aided by companion biomarkers

• new therapeutic protein-drugs that are efficacious and safe

• remote sampling with a drop of blood collected by the consumer or the patient

• accessible, affordable testing for health, diagnosis and disease management